logotype
  • Home
  • About Us
  • Events
    • Upcoming Conferences
    • Past Conferences
  • Event Support
  • Careers
  • Contact Us
logotype
  • Home
  • About Us
  • Events
    • Upcoming Conferences
    • Past Conferences
  • Event Support
  • Careers
  • Contact Us
  • Home
  • About Us
  • Events
    • Upcoming Conferences
    • Past Conferences
  • Event Support
  • Careers
  • Contact Us
logotype
logotype
  • Home
  • About Us
  • Events
    • Upcoming Conferences
    • Past Conferences
  • Event Support
  • Careers
  • Contact Us
March 15, 2024

Gilead To Acquire Bio/Pharma Company CymaBay for $4.3 Bn

by info@virtueinsight.comNews0 Comments

Gilead has agreed to acquire CymaBay, a Newark, California-based clinical-stage bio/pharmaceutical company, for $4.3 billion. CymaBay’s lead candidate is seladelpar, an oral drug for treating primary biliary cholangitis (PBC), a rare, chronic, cholestatic liver disease.

Under the agreement, a wholly owned subsidiary of Gilead will commence a tender offer to acquire all of the outstanding shares of CymaBay’s common stock at a price of $32.50 per share in cash.

“We are looking forward to advancing seladelpar by leveraging Gilead’s long-standing expertise in treating and curing liver diseases,” said Daniel O’Day, the company’s chief executive.

“Building on the strong research and development work by the CymaBay team to date, we have the potential to address a significant unmet need for people living with PBC and expand on our existing broad range of transformational therapies,” he added. Gilead expects the deal to close quickly, before the end of the first quarter.

The transaction was approved by both the Gilead and CymaBay Boards of Directors and is anticipated to close during the first quarter of 2024, subject to regulatory approvals and other customary closing conditions.

Visit our upcoming pharma conferences – https://virtueinsight.com/upcoming-conferences/

anticounterfeiting biosimilars biotech biotechnology clinicaltrials Counterfeit healthcare pharma pharmaceutical pharmacovigilance pharmaindustry pharmareglatory serialazation supplychain
prev

Kyowa Kirin to acquire Orchard Therapeutics in deal worth $477m

next

AstraZeneca completes Icosavax acquisition for $1.1bn

RELATED POSTS

August 10, 2022
News

GSK Acquires Bellus Health for $2 Billion

read more
September 6, 2023
News

Otsuka Pharmaceutical to Acquire Mindset Pharma

read more

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

logotype

We strive to produce high quality conferences which include the latest topics which are delivered by world class leaders of the industry.

Facebook-fTwitterYoutubeLinkedin-inInstagramPinterest

Quick Links

About us
Contact us
Event Support
Careers
Privacy Policy
Terms & Conditions

Subscribe to our newsletter

    © 2025 Virtue Insight. All rights reserved.